cnbc.com / .cnbc-com-health-care

The U.S. Food and Drug Administration is shuffling its top drug and biologics regulators, days after the departure of former commissioner Marty Makary.

U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.

The CDC said the risk to the general public from hantavirus remains low.

Biogen said signals sugget the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose.

For some experts, the outbreak is raising broader concerns about how equipped the U.S. is to respond to future infectious disease threats.

Makary's tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.

Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.

CNBC's Jim Cramer said today's market may resemble 1999 in some ways, but investors are punishing stocks even more aggressively.

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines.

Remote expedition cruises to destinations like Antarctica and the Arctic are booming, but the deadly hantavirus aboard MV Hondius is a reminder of unique risks.